Author

Karolina Borankova

Masaryk UniversityORCID 0000-0003-2406-8109Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:gene regulatory network inference· 1 Approach:statistical model· 1

Frequent Co-Authors

Jan SkodaiD· 2 shared Adela KubistovaiD· 1 shared I. R. HorakiD· 1 shared Jaroslav ŠtěrbaiD· 1 shared Mária KrchniakováiD· 1 shared Marie ŠulováiD· 1 shared Martin MarekiD· 1 shared Matyas Solny· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

9 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Jan SkodaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintOct 1, 2026

Cumate-inducible models of MYC-driven neuroblastoma identify mitoribosomal synthetic lethality as a precision oncology vulnerability in MYC(N)-amplified tumors

Adela Kubistova, I. R. Horak, Tomáš Bárta…·Jan Skoda

This paper develops a cumate-inducible model to study MYC-driven neuroblastoma and identifies mitoribosomal synthetic lethality as a therapeutic target in MYC(N)-amplified tumors.

DOI 10.64898/2026.05.25.725359

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyLife Science AlliancePeer-reviewedDec 6, 2024

Depletion of chemoresponsive mitochondrial fission mediator DRP1 does not mitigate sarcoma resistance

Karolina Borankova, Matyas Solny, Mária Krchniaková, Jan Skoda

This study shows that reducing DRP1 activity in pediatric sarcomas does not improve drug sensitivity, suggesting DRP1 is not a key driver of chemoresistance in these cancers.

4 citations

humanbulk RNA-seq

𝕏 PostBluesky